Cefosin injections 1gr #1

Cefosin instruction

You can buy Cefosin here

Composition

One bottle contains:
active substance - cefotaxime sodium (in terms of cefotaxime) - 1 g.

Pharmacokinetics

After a single intravenous dose of 1 g Cefosin, the time to reach the maximum concentration is 5 minutes, the maximum concentration is 101.7 µg / ml. After intramuscular administration in a dose of 1 g, the time to reach the maximum concentration is 0.5 h and is 21 μg / ml. Communication with plasma proteins - 30-50%. Bioavailability - 90-95%.
Creates therapeutic concentrations in most tissues (myocardium, bones, gallbladder, skin, soft tissues) and fluids (synovial, pericardial, pleural, sputum, bile, urine, cerebrospinal fluid) of the body. The volume of distribution is 0.25-0.39 l / kg.
The half-life is 1 hour with intravenous administration and 1-1.5 hours with intramuscular administration. In chronic renal failure and in elderly people, the elimination half-life increases by 2 times. The elimination half-life in newborns is 0.75-1.5 h, in premature infants (body weight less than 1500 g) increases to 4.6 h; in children weighing more than 1500 g - 3.4 hours. With repeated intravenous administrations at a dose of 1 g every 6 hours for 14 days, cumulation is not observed. Cefotaxime passes through the placenta and passes into breast milk.
It is excreted by the kidneys - 20-36% unchanged, the rest is in the form of metabolites (15-25% in the form of pharmacologically active desacetylfotaxime and 20-25% in the form of 2 inactive metabolites M2 and M3).

Pharmacodynamics

III generation cephalosporin antibiotic for parenteral administration. Effective bactericidal, disrupting the synthesis of the cell wall of microorganisms. It has a wide spectrum of action.
Active against gram-positive and gram-negative microorganisms resistant to other antibiotics: Staphylococcus spp. (including Staphylococcus aureus (including strains that form penicillinase) and Staphylococcus aparatmidis (with the exception of Staphylococcus epidermidis and Staphylococcus aureus, methicillin-resistant), Streptococcus pneumoniae, Streptococcus pyogenes, anchors), Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pyogenes, Streptococcus pneumonia, Streptococcus pneumonia) Escherichia coli, Haemophilus influenzae (including strains that form penicillinase), Haemophilus parainfluenzae, Moraxella catarrhalis, Klebsiella spp. (including Klebsiella pneumoniae), Morganella morganii, Neisseria gonorrhoeae (including strains that form penicillinase), Acinetobacter spp., Corynebacterium diphtheriae, Erysipelothrix rhusiopathiae, Eubacter spp., phytheriae, Erysipelothrix rhusiopathiae, Eubacterium diphtheriae, Erysipelothrix rhusiopathiae, Eubacter sph. (including Clostridium perfringens), Citrobacter spp., Proteus mirabilis, Proteus vulgaris, Providencia spp. (including Providencia rettgeri), Serratia spp., some strains of Pseudomonas aeruginosa, Neisseria meningitidis, Bacteroides spp. (including some strains of Bacteroides fragilis), Fusobacterium spp. (including Fusobacterium nucleatum), Peptococcus spp., Peptostreptococcus spp.
Most strains of Clostridium difficile are resistant.
Resistant to most beta-lactamase gram-positive and gram-negative microorganisms.

Indications for Cefosin

- meningitis
- infections of the respiratory tract and ENT organs
- urinary tract infections
- infections of bones and joints
- skin and soft tissue infections
- infections of the pelvic organs
- gonorrhea
- infected wounds and burns
- peritonitis
- sepsis
- abdominal infections
- endocarditis
- Lyme disease
- salmonellosis
- infections on the background of immunodeficiency
- preoperative prophylaxis of infections, prevention and treatment of infections after surgical operations (including urological, obstetric-gynecological, in the gastrointestinal tract)

Dosage and administration

Intravenous (struino or drip), intramuscularly.
Adults and children with a body weight of 50 kg or more: with uncomplicated infections, as well as urinary tract infections - intramuscularly or intravenously, 1 g of Cefosin every 8-12 hours; with uncomplicated acute gonorrhea - intramuscularly, 1 g once; for moderate infections - intramuscularly or intravenously, 1-2 g every 12 hours; in case of severe infections, for example, in case of meningitis, intravenously, 2 g every 4-8 hours, the maximum daily dose is 12 g. The duration of treatment is determined individually.
In order to prevent infections, before surgery, it is administered during the initial general anesthesia once a year. If necessary, repeat the administration after 6-12 hours.
For caesarean section - at the time of application of the clamps on the umbilical vein - intravenously, 1 g of Cefosin, then 6 and 12 hours after the first dose - an additional 1 g.
With creatinine clearance of 20 ml / min / 1.73 m2 and less than the daily dose is reduced by 2 times.
Premature and newborns up to 1 week - intravenously, 50 mg / kg every 12 hours; at the age of 1-4 weeks - intravenously, 50 mg / kg every 8 hours; children weighing up to 50 kg - intravenously or intramuscularly (children over 2.5 years old), 50-180 mg / kg in 4-6 injections. In case of severe infections, incl. meningitis, the daily dose to children is increased to 100-200 mg / kg, intramuscularly or intravenously, in 4-6 doses, the maximum daily dose is 12 g.
Preparation of injection solutions: for intravenous injection, water for injections is used as a solvent (0.5-1 g is diluted in 4 ml of solvent, 2 g in 10 ml); for intravenous infusion, 0.9% sodium chloride solution or 5% dextrose solution is used as a solvent (1-2 g diluted in 50-100 ml of solvent). Duration of infusion - 50-60 minutes. For intramuscular injection use water for injection or 1% lidocaine solution (for a dose of 1 g - 4 ml).

Side effects of Cefosin

- urticaria, chills or fever, rash, pruritus, bronchospasm, eosinophilia, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell's syndrome), angioedema, anaphylactic shock
- nausea, vomiting, diarrhea or constipation, flatulence, abdominal pain, dysbacteriosis, abnormal liver function (increased activity of liver transaminases, alkaline phosphatase, hypercreatininemia, hyperbilirubinemia), stomatitis, glossitis, pseudomembranous enterocolitis, hepatitis, jaundice
- leukopenia, neutropenia, granulocytopenia, thrombocytopenia, hemolytic anemia, hypocoagulation, agranulocytosis
- renal dysfunction (azotemia, increased concentration of urea in the blood, oliguria, anuria, interstitial nephritis)
- headache, dizziness, encephalopathy, movement disorders, convulsions
- false positive Coombs reaction
- potentially life-threatening arrhythmias after a quick bolus injection into the central vein
- phlebitis, soreness along the vein, soreness and infiltration at the site of intramuscular injection
- superinfection (in particular, candidal vaginitis)
- phlebitis, soreness along the vein, soreness and infiltration at the site of intramuscular injection

Contraindications for Cefosin

- hypersensitivity (including to penicillins, other cephalosporins, carbapenems)
- intracardiac blockade without an established pacemaker
- severe heart failure
- hypersensitivity to lidocaine or another local amide-type anesthetic
- the presence of bleeding in history
- pregnancy and lactation
- children's age up to 2.5 years

Drug interactions

Increases the risk of bleeding when combined with antiplatelet agents, anticoagulants, nonsteroidal anti-inflammatory drugs.
The likelihood of kidney damage is increased when taken simultaneously with aminoglycosides, polymyxin B and “loop” diuretics.
Drugs that block tubular secretion, increase plasma concentrations of cefotaxime and slow down its excretion.
Pharmaceutically incompatible with solutions of other antibiotics in the same syringe or dropper.

special instructions for Cefosin

With care: the neonatal period, chronic renal failure, ulcerative colitis (including in history).
In the first weeks of treatment, pseudomembranous colitis may occur, manifested by severe prolonged diarrhea. At the same time stop taking Cefosin and prescribe adequate therapy, including vancomycin or metronidazole.
Patients with a history of allergic reactions to penicillins may have an increased sensitivity to cephalosporin antibiotics.
In case of drug treatment over 10 days, control of the number of blood corpuscles is necessary.
During treatment with Cefosin, it is possible to obtain a Coombs false positive test and a false positive reaction of urine to glucose.
With the simultaneous use of Cefosin and ethanol, disulfiram-like reactions may develop (facial flushing, abdominal cramps, nausea, vomiting, headache, lowering blood pressure, tachycardia, shortness of breath).

Features of the effect of Cefosin on the ability to drive a vehicle or potentially dangerous machinery

When using the drug Cefosin may occur: headache, dizziness, nausea, vomiting, abdominal pain, therefore, at the time of treatment should refrain from driving a vehicle or potentially dangerous mechanisms.

Overdose

Symptoms: convulsions, encephalopathy (in the case of the administration of large doses, especially in patients with renal insufficiency), tremor, neuromuscular excitability.
Treatment: symptomatic. There is no specific antidote.

Release form and packaging

Powder for solution for intravenous and intramuscular injection of 1 g in vials with a capacity of 10 ml.
1 g of the active substance in vials of colorless glass with a capacity of 10 ml, hermetically sealed with rubber stoppers, aluminum caps or aluminum caps combined with aluminum caps with plastic caps. On the plastic cover is applied the trademark of the enterprise.
On each bottle, stick a self-adhesive label or a label from a transparent polymer film.
1 bottle with the instruction on a medical use in the state and Russian languages ​​is placed in a pack from a cardboard.
50 bottles with 10 instructions for medical use in the state and Russian languages ​​are placed in a cardboard box.

Storage conditions

Store in a dark place at a temperature not exceeding 25 ° C.
Keep out of the reach of children!
Shelf life - 3 years.
Do not use after expiration date.

Terms of sell

You don't need a prescription to buy Cefosin.